Calogero Vetro

33PUBLICATIONS
118CO-AUTHORS
NanomedicineMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (33)

|Aug 17, 2026
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.

|Feb 27, 2026
Integrating Genomic and Clinical Data in AML: Real-World Application of the Sanger Multistage Model.

Andrea Duminuco, Silvia Rita Vitale, Antonella Nardo

|Feb 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Raffaele Palmieri, Fabio Guolo, Luana Fianchi

|Feb 11, 2026
Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Salvatore Perrone, Andrea Corbingi, Calogero Vetro

|Jan 28, 2026
BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Andrea Duminuco, Paola De Luca, Gaia Stanzione

|Jan 13, 2026
NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Calogero Vetro, Irene Azzali, Elisabetta Petracci

Pageof 6

Frequent Collaborators

13 joint publications

Giuseppe Alberto Palumbo

13 joint publications

Andrea Duminuco

9 joint publications

Fanny Erika Palumbo

9 joint publications

Maria Paola Martelli